ARVC2
FAMRCi001-A
General
Donor Information
General Donor Information |
|
Sex | female |
Age of donor (at collection) | 10-14 |
Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Disease associated phenotypes |
|
Is clinical information available? | yes |
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
Other cell lines of this donor | |
External Databases (Donor) |
|
BioSamples | SAMEA104387931 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | Yes |
Please provide the contact information | Local ethical committee of Federal Almazov North-West Medical Research Centre |
Is there other documentation provided to the donor for consenting purposes? | No |
Confirm that consent was obtained by a qualified professional | Yes |
Has the donor agreed to be re-contacted? | Yes |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent permit unforeseen future research, without further consent? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | No information |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Local ethical committee of Federal Almazov North-West Medical Research Centre |
Approval number | №13/19.06.2014 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | Local ethical committee of Federal Almazov North-West Medical Research Centre |
Approval number | №13/19.06.2014 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
An adult mesenchymal stem cell derived from adipose tisssue.
Synonyms
|
Source cell origin |
Portion of connective tissue composed of adipocytes enmeshed in areolar tissue
Synonyms
|
Age of donor (at collection) | 10-14 |
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Is reprogramming vector detectable? |
No |
Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Gelatin | |||||||||||||||||||||
Feeder cells |
mouse embryonic fibroblasts Cellfinder Ont Id: EFO_0004040 |
|||||||||||||||||||||
Passage method |
Enzymatically
Collagenase
|
|||||||||||||||||||||
CO2 Concentration | 5 % | |||||||||||||||||||||
Medium |
Other medium:
Base medium: KO-DMEM
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
|||||||||||||||||||||
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
|||||||||||||||||||||
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
|||||||||||||||||||||
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
POU5F1 (OCT-4) |
Yes |
|
|
|||
NANOG |
Yes |
|
|
|||
SOX2 |
Yes |
|
||||
TRA 1-60 |
Yes |
|
||||
TRA 1-81 |
Yes |
|
Differentiation Potency
Microbiology / Virus Screening |
|
Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
46,XX
Passage number: 10
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.